Distinguished in Pseudobulbar Affect

Orla Hardiman

Pearse Street, 
Dublin, L, IE 
Distinguished in Pseudobulbar Affect
Pearse Street, 
Dublin, L, IE 
OverviewLocationsClinical Research

Overview

Orla Hardiman practices in Dublin, Ireland. Hardiman is rated as a Distinguished expert by MediFind in the treatment of Pseudobulbar Affect. Their top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Pseudobulbar Affect, Frontotemporal Dementia, and Gastrostomy.

Their clinical research consists of co-authoring 361 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 10 articles in the study of Pseudobulbar Affect.

Locations

Pearse Street, Dublin, L, Ireland
Other Locations
College Green, Dublin, L, Ireland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, Parallel-group Clinical Trial to Assess the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% DIF in Patients With Post-Polio Syndrome
A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, Parallel-group Clinical Trial to Assess the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% DIF in Patients With Post-Polio Syndrome
Enrollment Status: Terminated
Publish Date: November 27, 2023
Intervention Type: Drug, Biological
Study Drug: Flebogamma
Study Phase: Phase 2/Phase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-004 Administered Intrathecally to Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-004 Administered Intrathecally to Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)
Enrollment Status: Terminated
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: WVE-004
Study Phase: Phase 1/Phase 2
Safety and Efficacy of Tauroursodeoxycholic (TUDCA) as add-on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis (ALS)
Safety and Efficacy of Tauroursodeoxycholic (TUDCA) as add-on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis (ALS)
Enrollment Status: Unknown
Publish Date: July 10, 2023
Intervention Type: Drug
Study Drug: Tauroursodexycholic Acid
Study Phase: Phase 3
View 2 Less Clinical Trials

360 Total Publications

A Proposed Feasibility Process: Lessons Learned from the Precision MS Project.
A Proposed Feasibility Process: Lessons Learned from the Precision MS Project.
Journal: Studies in health technology and informatics
Published: October 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Hardiman's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 21 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile